Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

On Thursday, Novavax Inc (NVAX) stock saw a decline, ending the day at $9.92 which represents a decrease of $-0.08 or -0.80% from the prior close of $10. The stock opened at $10 and touched a low of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...

Novavax (NVAX) ended the recent trading session at $10, demonstrating a -1.19% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.92%. At ...

The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines ...

Novavax's shares are tumbling after the company disclosed that regulators paused clinical trials for two key vaccine ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a ...

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined ...

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...